Of these abnormalities, the combination of hyposmia with colour vision impairment [20], and the combination of substantia nigra hyperechogenicity with decreased striatal dopamine transporter uptake [21] may identify those IRBD patients who are at increased short-term risk for being diagnosed with a synucleinopathy according to accepted clinical criteria. Here, SLC6A3 is linked to synucleinopathy.